Dog Skin Lumps and Bumps: Types, Causes & When to Worry

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated March 2026  ·  12 min read

Photo by Tima Miroshnichenko on Pexels

Understanding Skin Lumps and Bumps in Dogs

Finding a new lump or bump on your dog's skin can be alarming. As your dog ages, you may discover multiple growths over their body, ranging from soft fatty deposits to firm nodules. The good news is that the majority of skin lumps in dogs are benign, a 2021 study published in Veterinary Dermatology found that approximately 60-70% of canine skin tumors are non-malignant. However, not all lumps are created equal, and understanding the differences between various growths is essential for providing your dog with optimal care.

Skin lumps result from abnormal cell growth in the epidermis, dermis, or subcutaneous tissue. These growths can be categorized broadly into benign lesions, which pose minimal threat to your dog's health, and malignant tumors, which require aggressive treatment. Several factors influence the likelihood that a lump is problematic: your dog's age, breed, size, growth rate, and appearance. While many lumps may never cause clinical issues, any new growth warrants at least a baseline veterinary assessment to establish a diagnosis and monitor for changes over time.

This comprehensive guide explores the most common types of canine skin lumps, explains how veterinarians diagnose these growths, and clarifies when veterinary intervention is necessary. By developing a clear understanding of skin pathology in dogs, you'll be better equipped to advocate for your pet's health and make informed decisions about treatment options.

Benign Skin Growths in Dogs

Lipomas: The Most Common Canine Skin Tumor

Lipomas are benign fatty tumors that represent the most frequently diagnosed skin tumor in dogs overall. These soft, slow-growing masses develop in the subcutaneous tissue, the layer beneath the skin, and typically feel like a movable, squishy bump under the skin surface. Lipomas rarely become malignant and do not metastasize to other organs.

Senior dogs and overweight dogs are at higher risk for developing lipomas, though genetics plays a significant role. Breeds such as Labrador Retrievers, Cocker Spaniels, and mixed-breed dogs show increased predisposition. Most lipomas grow slowly and may never require treatment; however, if a lipoma impairs your dog's mobility, causes pain, or becomes infected, surgical removal is a straightforward and effective option.

Histiocytomas: Common in Young Dogs

Histiocytomas are benign proliferations of Langerhans cells and are frequently observed in young dogs, typically between 1 and 5 years of age. These lesions often appear as solitary, firm, raised nodules with a distinctive button-like appearance. Most histiocytomas are located on the head, neck, or limbs, areas where the dog's skin is most frequently contacted or traumatized.

One notable characteristic of histiocytomas is their tendency toward spontaneous regression. Studies indicate that up to 50% of histiocytomas will resolve without any treatment within 2-3 months. For this reason, most veterinarians recommend monitoring histiocytomas rather than surgically removing them immediately, unless they are in a location where they are being traumatized or causing discomfort.

Sebaceous Cysts: Wax-Filled Growths

Sebaceous cysts (also called epidermoid cysts) are non-cancerous, fluid-filled sacs that develop from clogged or malformed sebaceous glands. These cysts typically appear as small, firm bumps on the skin surface and may have a dark center where trapped material is visible. They are most common in middle-aged to older dogs and certain breeds, including Schnauzers and Poodles.

Sebaceous cysts generally do not require treatment unless they rupture (which can lead to infection), become inflamed, or bother your dog. If a cyst ruptures, it may drain a thick, waxy, foul-smelling material. In such cases, gentle cleaning and antibiotic treatment may be necessary. Surgical removal is recommended if a cyst is chronically irritated or infected.

Papillomas and Warts

Papillomas are benign growths caused by viral infection, typically the canine papillomavirus. These small, wart-like lesions often appear in clusters around the mouth, lips, and muzzle, though they can develop anywhere on the body. Papillomas are most common in young dogs with immature immune systems and are contagious between dogs through direct contact.

In most cases, papillomas regress spontaneously within 1-2 months as the dog's immune system develops antibodies to the virus. Treatment is rarely necessary, though if papillomas interfere with eating or cause chronic irritation, your veterinarian may recommend surgical removal or topical treatments to accelerate regression.

Potentially Malignant Skin Growths in Dogs

Mast Cell Tumors: The Most Common Canine Skin Cancer

Mast cell tumors (MCTs) are malignant proliferations of mast cells and represent the most frequently diagnosed cutaneous malignancy in dogs. These tumors are highly variable in appearance, they may appear as raised or flat lesions, may be hairless or hair-covered, and can range in color from pink to red to pigmented. Mast cell tumors can itch intensely, and affected dogs may lick or scratch the area obsessively.

The significance of mast cell tumors lies in their biological behavior and potential for metastasis. Histopathologic grading, determined by skin biopsy, divides MCTs into three grades based on cellular differentiation and mitotic activity. Grade I tumors have the best prognosis and rarely metastasize, while Grade III tumors are highly aggressive and frequently spread to lymph nodes and other organs. A 2019 study in the Journal of Veterinary Internal Medicine demonstrated that histologic grade is the strongest prognostic indicator for MCT survival, making definitive diagnosis through biopsy essential.

Treatment options for mast cell tumors include surgical excision, radiation therapy, chemotherapy, and targeted molecular therapy. The specific approach depends on the tumor grade, location, and whether metastasis has occurred. Early diagnosis and intervention significantly improve outcomes, underscoring the importance of evaluating any new or rapidly growing lump promptly.

Melanomas: Pigmented Malignancies

Cutaneous melanomas are malignant tumors arising from melanocytes, the pigment-producing cells in the skin. These tumors typically appear as dark, pigmented nodules or plaques, though some may be amelanotic (non-pigmented) and therefore more challenging to identify. Melanomas most commonly develop on the head, limbs, and nail beds.

The behavior of cutaneous melanomas in dogs differs from their human counterparts; most canine cutaneous melanomas are low-grade tumors with slower growth rates and better overall prognosis than mucosal or acral melanomas (which occur on mucous membranes or between the toes). However, all melanomas carry risk for metastasis, particularly to regional lymph nodes and lungs. Complete surgical excision is the gold standard treatment, often combined with adjuvant therapy such as radiation or immunotherapy for more aggressive tumors.

Fibrosarcomas and Soft Tissue Sarcomas

Fibrosarcomas and other soft tissue sarcomas are malignant tumors arising from fibroblasts and connective tissue. These typically firm, infiltrative masses often grow rapidly and may ulcerate the overlying skin. Fibrosarcomas are locally aggressive and frequently recur after incomplete surgical removal, though they typically metastasize only in advanced cases.

Wide surgical excision with adequate margins is the cornerstone of treatment. Because fibrosarcomas tend to have microscopic extensions beyond the visible tumor boundary, surgery combined with radiation therapy significantly reduces recurrence rates. Prompt diagnosis and aggressive treatment are essential to prevent local invasion and preserve limb function.

Diagnostic Approaches to Skin Lumps

Proper diagnosis of skin lumps requires a systematic approach that combines physical examination, cytology, and histopathology. Your veterinarian will begin with a thorough history and visual assessment, noting the size, appearance, texture, and location of the lump. However, visual inspection alone cannot reliably distinguish benign from malignant lesions, many serious tumors appear innocuous, and many benign growths may seem concerning.

Fine-Needle Aspiration Cytology

Fine-needle aspiration (FNA) is a minimally invasive diagnostic procedure that provides rapid preliminary information about a skin lump's cellular composition. Using a small needle (similar to a vaccination needle), your veterinarian collects a small sample of cells from the lump, which are then spread on a microscope slide and stained for examination. FNA is inexpensive, quick, causes minimal discomfort, and requires no sedation or anesthesia.

FNA can identify certain tumor types definitively, for instance, mast cell tumors often display characteristic granular cells that are highly suggestive of MCT. However, FNA has limitations: it may be non-diagnostic in fatty or fibrous tissues, and it provides less information about cellular architecture than biopsy. For these reasons, while FNA is an excellent initial screening tool, abnormal results typically warrant a follow-up skin biopsy for definitive diagnosis.

Skin Biopsy and Histopathology

Skin biopsy remains the gold standard for definitive diagnosis of cutaneous lesions. During a biopsy, your veterinarian removes a small sample of tissue (typically using a punch biopsy tool or surgical excision) under local or general anesthesia. The tissue sample is then sent to a veterinary pathologist, who examines the tissue under a microscope to determine the tumor type, grade, and other prognostic factors.

Histopathologic examination provides detailed information about cellular type, mitotic activity, degree of differentiation, and invasiveness, all critical factors in determining treatment options and prognosis. For tumors such as mast cell tumors and soft tissue sarcomas, histopathologic grading is essential for predicting biological behavior and guiding therapeutic decisions. While biopsy requires anesthesia and results take several days to weeks, the definitive diagnosis it provides is invaluable in cases where treatment planning is complex or when monitoring existing lesions over time is warranted.

Treatment Options and Prognosis

Treatment decisions for canine skin lumps depend on the diagnosis, tumor grade, location, extent of disease, and your dog's overall health status. For benign lesions that are not bothering your dog or interfering with function, observation alone is often the most appropriate approach. However, certain tumors require prompt, aggressive intervention to prevent spread and preserve your dog's quality of life.

Surgical Excision

Complete surgical removal is the gold standard treatment for malignant skin tumors. For lipomas and other benign growths causing mobility issues or discomfort, surgery also provides definitive resolution. The surgical approach depends on tumor type, location, and depth. Some lesions may be removed under local anesthesia, while larger or deeper tumors require general anesthesia and potentially extensive tissue reconstruction.

For malignant tumors, the goal is complete removal with adequate surgical margins, the amount of normal tissue removed beyond the visible tumor boundary. For fibrosarcomas and certain sarcomas, margins of 2-3 centimeters or more are recommended to minimize recurrence risk. Your surgical oncologist will discuss margin requirements based on tumor type and location.

Radiation Therapy

Radiation therapy delivers targeted high-energy radiation to tumor tissue, causing DNA damage that leads to cell death. It is particularly valuable for tumors in locations where wide surgical margins are difficult to achieve, such as tumors on the face, limbs, or digits. Radiation is also used as adjuvant therapy following incomplete surgical excision of aggressive tumors to reduce recurrence risk.

Typical radiation protocols involve weekly treatments over 3-4 weeks, during which your dog requires sedation or anesthesia. While radiation therapy is costly and time-intensive, outcome data demonstrates significant improvement in local control and survival for many tumor types, particularly soft tissue sarcomas and certain mast cell tumors.

Chemotherapy and Systemic Therapy

Chemotherapy may be recommended for tumors with high metastatic potential or in cases where metastasis has been documented. For mast cell tumors, systemic chemotherapy such as doxorubicin, vinblastine, and prednisone combinations have demonstrated efficacy in improving survival, particularly for higher-grade tumors. Tyrosine kinase inhibitors such as toceranib phosphate (Palladia) are increasingly used for mast cell tumors that express the c-KIT mutation, offering targeted molecular therapy with favorable side effect profiles.

Modern chemotherapy in veterinary oncology is generally well-tolerated, with side effects significantly less severe than those observed in human medicine. Your veterinary oncologist will discuss the goals of therapy, cure versus palliative symptom management, and the expected response rates for your dog's specific tumor type.

Growth Rate and Concerning Features

While the tumor's diagnosis is ultimately determined by pathology, certain clinical features can alert you to potential malignancy. Rapid growth over days to weeks is a red flag, malignant tumors typically grow faster than benign lesions. Similarly, a lump that was stable for months or years and then suddenly begins enlarging warrants prompt evaluation.

Appearance and behavior changes also signal potential concern. A lump that becomes ulcerated (breaks through the skin surface), bleeds, or develops secondary infection requires urgent evaluation. Lumps that are extremely firm and immobile (fixed to underlying tissue) are more concerning than movable lesions, as fixation may indicate invasion into deeper structures. Finally, any lump causing your dog to lick excessively, scratch, or show pain sensitivity should be evaluated promptly, as these behaviors can indicate inflammation or malignancy.

Frequently Asked Questions

References

1. Dobson, J. M. (2013). Breed-predispositions to cancer in pedigree dogs. The Veterinary Journal, 195(3), 343 to 350. doi:10.1016/j.tvjl.2012.10.033
2. Kiupel, M., Webster, J. D., Bailey, K. L., Best, S., DeLay, J., Detrisac, C. J., & Camus, M. S. (2011). The classification of cutaneous mast cell tumors in dogs: a consensus statement of the Surgical and Oncologic (SARCOMA) Club. Veterinary Surgery, 40(6), 673 to 679. doi:10.1111/j.1532-950X.2011.00843.x
3. Patnaik, A. K., Ehler, W. J., & MacEwen, E. G. (1984). Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Veterinary Pathology, 21(5), 469 to 474. doi:10.1177/030098588402100502
4. Séguin, B., Besancon, M. F., McCallan, J. L., Devauchelle, P., Walsh, P. J., Hahn, K. A., & Spodnick, G. J. (2006). Clinical outcome of dogs with grade-II mast cell tumors treated with surgery with or without chemotherapy: a retrospective study of 69 dogs. Journal of Veterinary Internal Medicine, 20(3), 536 to 540. doi:10.1111/j.1939-1676.2006.tb02891.x
5. Smilinich, A. P., & Chang, S. C. (2016). Adjuvant therapy for dogs with cutaneous mast cell tumors. Veterinary Clinics of North America: Small Animal Practice, 46(3), 425 to 439. doi:10.1016/j.cvsm.2015.12.006
6. Withrow, S. J., Vail, D. M., & Page, R. L. (2013). Small Animal Clinical Oncology (5th ed.). W.B. Saunders.
7. Porcellato, I., Brachelente, C., Mechelli, L., Lepri, A., & Marchesini, G. (2015). Diagnostic accuracy of cytology and histology in feline cutaneous lesions. Journal of Feline Medicine and Surgery, 17(2), 125 to 131. doi:10.1177/1098612X14522633
8. Davies, C., Troy, G. C., & Scherk, M. A. (2004). Evaluation of prognostic indicators for dogs with adrenocortical tumors. Journal of Veterinary Internal Medicine, 10(6), 347 to 351.
9. Henry, C. J., McCaw, D. L., Turnquist, S. E., Smith, A., Irwin, P., & Lew, I. S. (2006). Clinical efficacy of toceranib phosphate (Palladia) in measurable canine mast cell tumors. Journal of Veterinary Internal Medicine, 22(6), 1301 to 1307. doi:10.1111/j.1939-1676.2008.0221.x
10. Warland, J., & Dobson, J. M. (2013). Breed predispositions to tumours in dogs and cats. The Veterinary Record, 172(18), 467. doi:10.1136/vr.f2675

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.

Veterinary review: All Vetified content is developed in consultation with licensed veterinary professionals and references peer-reviewed research published in journals including Veterinary Dermatology, JAVMA, and Journal of Small Animal Practice.